Compare Datadog Inc (DDOG) vs DexCom, Inc. (DXCM) Price & Performance

Datadog (DDOG) trades at $260.24, up 1.05% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.58. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margin is modest at 3.69%. The company's acquisition of Adaptive ML aims to bolster its AI capabilities, positioning it for sustained growth in cloud observability.

The outlook for DDOG is positive, driven by solid revenue expansion and strategic AI investments, but high valuation multiples (P/E of 667.28, P/S of 25.79) pose risks if growth slows. Investor sentiment is overwhelmingly bullish, with 83% of analysts rating it a buy, though competition and market volatility require monitoring. The stock's momentum and institutional backing suggest further upside, contingent on continued execution and market conditions.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.